摘要
我国是世界上老年人口最多的国家,多病共存的老年人多重用药情况不可避免且非常普遍。因此,越来越多医学和药学专家呼吁广大医务人员关注老年人多重用药的风险,并提出管理措施,以求避免或减少多药联合治疗时药物相互作用带来的损害。为了满足临床实践需求,进一步提高老年人群用药安全的水平,我国部分临床医学和药学专家经多次研讨,制定了本《老年人多重用药安全管理专家共识》以供临床参考,确保用药安全。
China has the largest elderly population in the world. Polypharmacy in the elderly with multiple diseases is inevitable and very common. In recent years, more and more medical and pharmaceutical experts appeal to pay attention to the risk of polypharmacy in elderly, and put forward management to avoid damage caused by drug interaction in multi-drug combination therapy. To meet the needs of clinical practice and further to improve the level of drug safety in elderly, a group of clinical medicine and pharmaceutical experts in China have worked out the ＂Expert Consensus on the Risk Management of Polypharmacy in Elderly＂ for clinical reference to ensure the safety of drug use.
作者
无
李光伟
Endocrinology and Metabolism Branch of Chinese Association of Geriatric Research;Committee of Clinical Toxicology of Chinese Society of Toxicology
出处
《中国药物警戒》
2018年第10期627-640,共14页
Chinese Journal of Pharmacovigilance
关键词
老年人
多重用药
安全管理
专家共识
elderly
polypharmacy
risk management
expert consensus
